olaparib | Olaparib

Keyword	CPC	PCC	Volume	Score	Length of keyword
olaparib	1.64	0.9	1502	11	8

Keyword	CPC	PCC	Volume	Score
olaparib	1.78	0.3	8512	40
olaparib ovarian cancer	0.65	0.6	385	32
olaparib package insert	1.35	0.4	9134	81
olaparib side effects	1.36	0.9	3243	10
olaparib dose	0.78	1	3621	85
olaparib prostate cancer	0.69	0.7	6932	78
olaparib breast cancer	1.89	0.3	1216	84
olaparib fda	1.44	0.5	9300	83
olaparib mechanism of action	0.75	0.3	4832	4
olaparib lynparza	1.65	0.1	1626	99
olaparib pi	1.14	0.3	2515	90
olaparib spc	0.23	0.6	8972	17
olaparib moa	1.7	0.7	551	3
olaparib cost	0.49	1	9758	71
olaparib fda label	0.74	0.7	2076	55
olaparib ic50	1.54	0.2	241	64
olaparib ema	0.43	0.1	8131	45
olaparib rcp	1.42	0.4	8339	100
olaparib prescribing information	0.12	0.9	6916	35
olaparib dose reduction	0.18	0.3	6274	50
olaparib pancreatic cancer	1.72	0.5	2185	6
olaparib maintenance ovarian cancer	1.99	0.9	3012	6
olaparib parp inhibitor	0.27	0.2	840	40
olaparib fda approval	1.56	0.4	3949	29
olaparib adjuvant breast cancer	1.55	0.5	1695	25
olaparib trial	1.74	0.3	1289	45
olaparib company	0.88	0.4	3723	57
olaparib brand name	0.88	1	3168	84
olaparib approval	0.22	0.6	3007	21

Search Results related to olaparib on Search Engine

Olaparib - Wikipedia
wikipedia.org:443

https://en.wikipedia.org:443/wiki/Olaparib

WEBOlaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.

DA: 81 PA: 17 MOZ Rank: 30

Olaparib: Uses, Dosage, Side Effects, Warnings - Drugs.com
drugs.com:443

https://www.drugs.com:443/olaparib.html

WEBNov 29, 2023 · Olaparib (Lynparza) is a PARP inhibitor used to treat types of breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, fallopian tube cancer, or peritoneal cancer. Olaparib works by blocking a protein called PARP which helps cancer cells repair themselves, blocking PARP causes the cancer cells die.

DA: 90 PA: 44 MOZ Rank: 11

Olaparib - NCI - National Cancer Institute
cancer.gov:443

https://www.cancer.gov:443/about-cancer/treatment/drugs/olaparib

WEBOlaparib is approved to treat: Breast cancer that is HER2 negative and has certain germline mutations in the BRCA1 or BRCA2 gene. Olaparib is used after surgery in adults with: High-risk early-stage breast cancer that has been treated with …

DA: 1 PA: 3 MOZ Rank: 46

LYNPARZA® (olaparib) - Official Patient Website
lynparza.com:443

https://www.lynparza.com:443/

WEBLYNPARZA is a prescription medicine used to treat adults who have: advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene.

DA: 6 PA: 89 MOZ Rank: 2

Olaparib: MedlinePlus Drug Information
medlineplus.gov:443

https://medlineplus.gov:443/druginfo/meds/a614060.html

WEBOlaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells. How should this medicine be used? Olaparib comes as a tablet to take by mouth twice daily with or without food. Try to space your doses about 12 hours apart. Take olaparib at around the same times every day.

DA: 20 PA: 78 MOZ Rank: 8

olaparib oral: Uses, Side Effects, Interactions, Pictures ... - WebMD
webmd.com:443

https://www.webmd.com:443/drugs/2/drug-167487-1856/olaparib-oral/olaparib-tablet-oral/details

WEBGeneric Name: olaparib. This medication is used to treat certain cancers (such as breast, ovarian, fallopian tube, pancreatic, peritoneal cancer, prostate ). Olaparib works by...

DA: 39 PA: 67 MOZ Rank: 66

Olaparib (Lynparza) | Cancer information | Cancer Research UK
cancerresearchuk.org:443

https://www.cancerresearchuk.org:443/about-cancer/treatment/drugs/olaparib-lynparza

WEBHow does olaparib work? Olaparib is a targeted drug called a PARP inhibitor. PARP is a protein that helps damaged cells to repair themselves. Olaparib stops PARP working. Some cancer cells rely on PARP to keep their DNA healthy. This includes cancer cells with a change in the BRCA genes.

DA: 97 PA: 58 MOZ Rank: 17

Olaparib (Oral Route) Description and Brand Names - Mayo Clinic
mayoclinic.org:443

https://www.mayoclinic.org:443/drugs-supplements/olaparib-oral-route/description/drg-20127672

WEBOlaparib is used in combination with abiraterone and prednisone or prednisolone to treat metastatic castration-resistant prostate cancer (prostate cancer that has spread and is resistant to medical or surgical treatments that lower testosterone) with a certain type of inherited or acquired abnormal BRCA gene.

DA: 77 PA: 80 MOZ Rank: 85

FDA approves olaparib for adjuvant treatment of high-risk early …
fda.gov:443

https://www.fda.gov:443/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer

WEBOn March 11, 2022, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients with deleterious or suspected...

DA: 52 PA: 11 MOZ Rank: 32

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated …
nejm.org:443

https://www.nejm.org:443/doi/full/10.1056/NEJMoa2105215

WEBJun 3, 2021 · In the OlympiA trial, we hypothesized that olaparib would provide benefit as an adjuvant therapy for patients with germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant–associated early...

DA: 50 PA: 62 MOZ Rank: 100